jebkeiper.bsky.social

The difference between #techbio and #biotech is hubris. Where #techbio believes biological mystery can be overcome by more data and that the underlying mechanism is unimportant, #biotech (and it's children #synbio #engbio) believes that the mechanism itself will lead to new wonders

My latest is an in-depth look at China's scientific rise unnerving the US biotech industry. A 🧵: endpts.com/chinas-drug-...

Homeward bound. Farewell city by the bay and #JPM2025

The Biotech CEO Sisterhood stood out at #JPM2025 today. Proud to be an ally! #allyship

Biotech on Bluesky get a look first. RA Capital’s annual thoughts on how biotech can better (Semper Maior; always better). This one explore how we can elicit more candor. Some stories, too. And tons of top-down data analyzing 2024 performance & setup for 2025. rapport.bio/all-stories/...

Biotech on Bluesky, I’m sharing with you first. RA Capital just launched Biotech Unveiled, a free online course our team created. Learn at own pace. Covers fundamentals of how insurance + investment direct R&D. Essential knowledge for leaders. racap.thinkific.com/courses/biot...

Re-upping this reply thread from last night. Drugs don't come from nowhere, folks. And we're not ripping off the NIH, either.

Is it just me or is the biggest biotech / Pharma deal news this week going to be Centerview selling a stake?

He did it because he had a seven-year old daughter who had never seen one of his films and he wanted to make something she could see. He also said “I’m going to play this movie like I’m working with the Royal Shakespeare Company” www.gq.com/story/michae...

New York Times ‘Six Childhood Scourges We’ve Forgotten About, Thanks to Vaccines Most Americans, including doctors, have no memory of the devastating diseases that routinely threatened children until the 1960s.’

Time for a recap of what happened in #biotech this year. #biosky #chemsky

Kudos to both Vijay and Vineeta!

@lisamjarvis.bsky.social’s editorial on the shocking murder of UnitedHealth Insurance’s CEO is a must read, and masterclass on balanced perspectives. The health insurance “industry” has a basic economic principle incompatible with others in the ecosystem. Collect premiums, don’t pay claims.

Read further and found this alternative suggested by the strike organizers. Yoink!!

@dereklowe.bsky.social honing in on the same bottom line message from @wpwalters.bsky.social @prof-ajay-jain.bsky.social it's so true and hits so hard:

Between the earthquake/tsuanmi scare, the UnitedHealthcare shooting and the South Korea martial law stuff this week, it feels like Bluesky is getting more and more critical mass around breaking events that made Twitter so sticky and useful.

You may not understand why, but the healthcare insurance and PBM contracts YOU have signed for Tesla, SpaceX , @X, along with CEOs of other big companies , have more impact on healthcare costs and quality of care in this country, than anything you can do with DOGE

DiffDock, a new diffusion-based ligand docking program, made s big splash earlier this year. But it’s apparently not all it’s claimed to be:

Sometimes the combination of arrogance and ignorance is breathtaking. Yes, US health care has high admin costs; that's because it relies so much on private insurers. Govt-run health insurance has much lower overhead

@lifescivc.bsky.social blog on Atlas Venture's recent fundraising is a master class in biotech venture capital financial metrics. A must read. lifescivc.com/2024/12/atla...

I’ve worked with Ramy for years, and I completely agree that the overhype doesn’t help make medicines any faster. AI is a great tool, it’s not a solution in and of itself.

The fight between Eli Lilly and Novo Nordisk over the booming obesity drug market is intensifying now that manufacturing has ramped up. This Lilly-sponsored study is one jab.

This whole thread. The beauty of this platform…

Leveraging Dual-Ligase Recruitment to Enhance Protein Degradation via a Heterotrivalent Proteolysis Targeting Chimera | Collaboration with @georgwinter.bsky.social and Kristin Riching labs. Now published in Journal of the American Chemical Society @acsjacs.bsky.social pubs.acs.org/doi/10.1021/...

Thanksgiving is my & others’ favorite holiday. It reminds me of the Daniel Dafoe quote, “All our discontents about what we want appeared to me to spring from the want of thankfulness for what we have.” We are all so blessed. Give thanks. 🙏

Dr. Debby Day said her bosses at Cigna gave her a stark warning: Work faster, or the company might fire her. She said her bosses cared more about being fast than being right: “Deny, deny, deny. That’s how you hit your numbers.” www.propublica.org/a...

Some very good news for people with asthma and COPD. The first new treatment for acute attacks in over 50 years— a monoclonal antibody vs interleukin-5 receptor-α—with efficacy in a randomized trial www.thelancet.com/journals/lan...

Apolitical Thanksgiving topic www.technologyreview.com/2024/11/27/1...

Checkpoint therapy is only one (blunt) instrument for immune system modulation. HPK1 inhibition (IO small molecule, but not checkpoint) replicates checkpoint inhibitors activity on T cells while *enhancing* B cell activity (& dendritic cells). Check it out: www.nimbustx.com/wp-content/u...

www.wsj.com/health/pharm... Fascinating article about pediatric GLP1 usage. Underscores the critical importance of next generation obesity treatments, especially when we see youth begin regular incretin usage. @wsj.com #GLP1 #incretins #obesity #drugdiscovery

www.nature.com/immersive/d4... So awesome. Great datasets and tools for single-cell models.

ChemBio fans please repost the #ChemicalBiology Feed bsky.app/profile/thor... @carolynbertozzi.bsky.social @ritastrack.bsky.social @stephanhacker2.bsky.social @stuartcantrill.bsky.social @laurahowes.bsky.social @dirktrauner.bsky.social @chemjobber.bsky.social @dereklowe.bsky.social #chemsky

Had the privilege of being at the Atlas Venture retreat to see Bruce Booth give his “Year in Review 2024” talk and they managed to get it up online the next day. Well worth the watch (as always). We need to find a way to get Bruce over here to Bluesky #biotech. youtu.be/szwRUERnoOM?...

Biotech CEO forum recently shared that only a quarter of R&D stage biotechs had >24mo of cash on hand. What do you think primarily drives that distribution curve? Investors only want to risk 2yr or less cash? Said differently, investors need to see a valuation step up after 2yrs of investment?

First blue sky post. Thanks @daphnezohar.bsky.social for the LI post encouragement. Now I need to follow the right folks that took me a decade to curate on X. 🤪 #BioSky